Virtual ACC 2020 | More Evidence in Support of the Demanding 2017 Hypertension Guidelines

It’s been a while since the demanding and tough 2017 document written jointly between ACC and AHA where, with much controversy, cutoff hypertension values were taken to extreme limits. In fact, more flexible ESC guidelines came out a few months later.

Despite this document, hypertension-related cardiovascular death kept increasing in the US across all age subgroups and regions. 

Results from the present analysis are along the line of prior observational studies. The downward trend in cardiovascular mortality has been slowing down while death for cardiac failure has begun to climb. 

Data to be presented by Dr. Nambiar at the frustrated ACC 2020, to be published simultaneously in JACC, show death for hypertension adjusted by age every 100.000 persons has risen from 18.3 in 2007 to 23 in 2017 (p<0.001 for this trend).


Read also: Virtual ACC 2020 | Myocardial Ischemia Induced by Sudden Mental Stress.


During this same period, cardiovascular death related to hypertension increased 72% in rural US vs 20% in cities (p<0.001 for this trend).

Mortality has increased across all age groups, with the highest impact in people ranging from 65 to 74, for both sexes, but mostly for men.


Read also: Virtual ACC 2020 | “Dangerous” Plaques by CT Effectively Predict Infarction.


The reasons behind this increase are multiple, but clearly diabetes and hypertension epidemics weigh on.

Adjusting to the new cutoff values set in 2017 seems critical.

Original title: Decade long temporal trends in U.S. hypertension related cardiovascular mortality.

Reference: Nambiar L et al. J Am Coll Cardiol. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease

In patients with multivessel coronary artery disease who remain stable 12 months after drug-eluting stent (DES) stenting, there is uncertainty as to prolonging dual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....